Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
Oropharyngeal cancer (OPC) is a type of head and neck cancer and ~70% cases of OPC are associated with
high-risk (hr) human papillomaviruses (HPV) infection. OPC cancers are increasing in prevalence especially in
persons living with HIV (PWH) and this group also has higher rates on HPV associated OPC. Reasons for these
findings are not well understood. While antiretroviral treatment (ART) does diminish HIV replication and immune
activation, in a large majority of PWH it is generally started in chronic infection, when HIV reservoirs have already
been established and uncontrolled HIV replication has resulted in significant immune dysfunction. Based on our
preliminary data and what is known in the literature, we hypothesize that ongoing HIV replication and the resultant
production of its proteins upregulates oncogenic HPV proteins (E6 and E7) thereby enhancing the probability of
OPC development. HIV replication also results in exhaustion of CD8 T cells which is further exacerbated by
increased HPV replication making HPV-specific CD8 T cells especially prone to overstimulation and exhaustion.
These dysfunctional CD8 T cells thus make it even more likely for OPC to occur in PWH. Furthermore, both HIV
protein production and immune activation continue after potent ART is started. As such, production of HIV
proteins from previously latently infected CD4 T cells continues to drive HPV oncogenic protein production as
well as CD8 T cell exhaustion and OPC continues to occur at higher rates in these PWH. Solidifying this overall
hypothesis as proposed in our 3 aims would provide comprehensive insights into the mechanisms of OPC in
PWH leading to improved prevention and therapies. Our overall study hypothesis is that chronic inflammation
despite ART in PWH favors both persistence and proliferation of hrHPV16 infected oropharyngeal
epithelial cells and contributes to impaired anti-HPV specific T cell immunity leading to initiation of OPC.
We will test this hypothesis in the following three aims: In aim 1, we will determine the HPV types present in
OPC from PWH and how T cell mediated anti-tumor immunity is impaired. We will examine whether multiple
HPV subtypes persist. In addition, we will determine whether tumor and CD8 are spatially distant and whether
the intra-tumoral CD8 are exhausted. Our aim 2 will determine how an HIV infection influences HPV
infection, its gene expression and DNA replication to facilitate oncogenic transformation of
oropharyngeal epithelial cells. Using 3D based models, we will show that HIV infection via its specific proteins
(Tat and/or envelope gp120) modulates HPV pathogenesis by interfering at one or more steps in its life cycle.
In aim 3, we will determine the mechanisms of HPV specific CD8 T cell dysfunction in PWH with OPC and
whether tumor specific immunity can be restored. Our successfully completed studies will show how chronic,
albeit low grade inflammation in PWH on ART is beneficial to the initiation of HPV associated OPC via increased
susceptibility of epithelial cells to HPV infection, increased oncogene expression which when coupled with an
inability of CD8 T cells to kill HPV infected cells tips the balance of an HPV infected cells towards OPC initiation.
Public Health Relevance Statement
PROJECT NARRATIVE
Oropharyngeal cancer (OPC) is commonly associated with Human Papilloma Virus (HPV) infection. The goal of
this work is to understand how oropharyngeal cancer (OPC) is initiated when an individual is already infected
with another chronic virus like HIV. These studies will identify early virus induced changes in the host that lead
to OPC.
National Institute of Dental and Craniofacial Research
CFDA Code
121
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
20-September-2024
Project End Date
30-June-2029
Budget Start Date
20-September-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$672,147
Direct Costs
$452,624
Indirect Costs
$219,523
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Dental and Craniofacial Research
$672,147
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01DE033864-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01DE033864-01
Patents
No Patents information available for 1R01DE033864-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01DE033864-01
Clinical Studies
No Clinical Studies information available for 1R01DE033864-01
News and More
Related News Releases
No news release information available for 1R01DE033864-01
History
No Historical information available for 1R01DE033864-01
Similar Projects
No Similar Projects information available for 1R01DE033864-01